Finanzen von 4D Molecular Therapeutics Inc (FDMT)FDMT4D Molecular Therapeutics Inc

Evaluating the bottom line, 4D Molecular Therapeutics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -383007.14%, while the net margin is -342657.14%. These profitability ratios, combined with a Return on Equity (ROE) of -32.97%, provide a clear picture of how effectively FDMT converts its operational activities into shareholder value.

In the context of the broader market, FDMT competes directly with industry leaders such as CRGX and KOD. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, FDMT's gross margin of 100.00% stands against CRGX's N/A and KOD's N/A. Such benchmarking helps identify whether 4D Molecular Therapeutics Inc is trading at a premium or discount relative to its financial performance.